• OPEN AN ACCOUNT
Indian Indices
Nifty
25,145.50 -81.85
(-0.32%)
Sensex
82,029.98 -297.07
( -0.36%)
Bank Nifty
56,496.45 -128.55
( -0.23%)
Nifty IT
35,214.85 -115.95
( -0.33%)
Global Indices
Nasdaq
46,310.43 221.84
(0.48%)
Dow Jones
6,668.02 -7.70
(-0.12%)
Hang Seng
46,768.58 -1,320.22
(-2.75%)
Nikkei 225
9,452.77 9.90
(0.10%)
Forex
USD-INR
88.75 -0.06
(-0.07%)
EUR-INR
103.09 0.08
(0.07%)
GBP-INR
118.50 -0.08
(-0.06%)
JPY-INR
0.59 0.01
(0.97%)

EQUITY - MARKET SCREENER

Glenmark Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532296
INE935A01035
868.316327
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GLENMARK
28.52
53443.19
EPS(TTM)
Face Value()
Div & Yield %
66.4
1
0.13
 

SEPC gains on bagging Rs 75-cr supply order from Gefos Solutions
Sep 24,2025

The contract is slated for execution over 8 to 9 months.

The order, valued at Rs 75,19,78,000 will be fulfilled through a domestic supplier. The projects entail construction of residential buildings, with the supply covering all necessary construction materials.

SEPC clarified that neither the promoter, promoter group, nor group companies have any interest in Gefos Solutions, and the order does not constitute a related party transaction.

SEPC is engaged in providing end-to-end solutions to engineering challenges, offering multidisciplinary design, engineering, procurement, construction, and project management services.

The company’s consolidated net profit surged 104.8% YoY to Rs 16.55 crore in Q1 FY26, compared to Rs 8.08 crore in the year-ago quarter. Revenue from operations rose 15% YoY to Rs 202.28 crore from Rs 175.82 crore in Q1 FY25.